More on LONA
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $7.81 |
|
|||
| Open | $7.69 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $7.90 | ||||
| Day Low | $7.00 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 65,060 | ||||
- LeonaBio presents ALS drug at development summit, plans phase 2 trial
- LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit
- LeonaBio to Participate in Upcoming Medical and Industry Meetings in June
- Piper Sandler Starts LeonaBio (LONA) at Overweight
- LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
- LeonaBio adds three directors to board, John Fluke retires
- LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D.
- LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
- Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data
- LeonaBio (LONA) Reiterated at Overweight by Cantor Fitzgerald Amid Growing Investor Interest
Entities mentioned with LONA
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- Earnings | View Related Stories »
- Stanford | View Related Stories »
- Show More...
